Zobrazeno 1 - 10
of 186
pro vyhledávání: '"Belisari, A"'
Publikováno v:
Business Process Management Journal, 2019, Vol. 26, Issue 1, pp. 1-23.
Externí odkaz:
http://www.emeraldinsight.com/doi/10.1108/BPMJ-06-2018-0158
Autor:
Andrea Belisari, Sergio Iannazzo, Giuseppe Di Pasquale, Claudio Fresco, Lorenzo Giovanni Mantovani, Maria Pia Ruggeri, Danilo Toni, Raffaele Landolfi
Publikováno v:
Farmeconomia: Health Economics and Therapeutic Pathways, Vol 17, Iss 2, Pp 47-58 (2016)
BACKGROUND: Each drug therapy with an anticoagulant effect may require, in emergency conditions, a rapid and specific strategy for a prompt restoration of coagulation. Dabigatran is the first-in-class of the so-called new oral anticoagulants (NAO), t
Externí odkaz:
https://doaj.org/article/e141542ce4dc459bb7607f1b3b0a1966
Autor:
Alberto Migliore, Andrea Belisari, Lucia S. D'Angiolella, Emanuele Bizzi, Umberto Massafra, Prisco Piscitelli, Lorenzo Giovanni Mantovani
Publikováno v:
Farmeconomia: Health Economics and Therapeutic Pathways, Vol 15, Iss 4, Pp 139-146 (2014)
The present study aims at evaluating the economic impact of the use of hyaluronic acid (Hyalubrix®60/HyalOne) as an alternative to surgery in the treatment of hip osteoarthritis, consistently with the therapeutic protocol envisaged in the Ortobrix s
Externí odkaz:
https://doaj.org/article/c17a457f249044b79d6c281149c41472
Autor:
Andrea Belisari, Daria Bettoni, Paolo Angelo Cortesi, Lucia Sara D'Angiolella, Lorenzo Giovanni Mantovani, Gerardo Miceli Sopo, Marino Nonis
Publikováno v:
Farmeconomia: Health Economics and Therapeutic Pathways, Vol 18, Iss 1S (2017)
To date, there are few therapeutic answers for Idiopathic pulmonary fibrosis (IPF) and only two pharmacological treatments have a marketing authorization for this disease. Recently nintedanib (Ofev®) has been authorized as a new therapeutic option a
Externí odkaz:
https://doaj.org/article/2a24935a133b42379858482a16b8b7a9
Autor:
Scalone, Luciana, Cortesi, Paolo A., Ciampichini, Roberta, Belisari, Andrea, D’Angiolella, Lucia S., Cesana, Giancarlo, Mantovani, Lorenzo G.
Publikováno v:
In Value in Health July-August 2013 16(5):814-822
Autor:
Massimo Antonelli, Giorgio Conti, Andrea Belisari, Lucia S. D'Angiolella, Lorenzo Mantovani, Sabato Montella, Patrizio Piacentini, Marco Ranieri
Publikováno v:
Farmeconomia: Health Economics and Therapeutic Pathways, Vol 14, Iss 1S, Pp 1-28 (2013)
The goals and recommendations for ICU (Intensive Care Unit) patients’ sedation and analgesia should be to have adequately sedated patients who are calm and arousal, so that they can guarantee a proper evaluation and an adequate control of pain. Thi
Externí odkaz:
https://doaj.org/article/afcb7ff051024c45a07f3647c63f54f0
Autor:
Carlo Barone, Andrea Belisari, Fortunato Ciardiello, Lorenzo Mantovani, Lucia D’Angiolella, Gianluca Furneri, Nicola Normanno, Patrizio Piacentini, Carmine Pinto
Publikováno v:
Farmeconomia: Health Economics and Therapeutic Pathways, Vol 13, Iss 1S, Pp 1-80 (2012)
The present health technology assessment report evaluates the clinical and economic profile of cetuximab in first-line metastatic colorectal cancer (mCRC) in Italy. The first part of the report addresses the epidemiological, clinical, social and econ
Externí odkaz:
https://doaj.org/article/aed409f9942b477087115ec46c5b46f7
Autor:
Marco Cristiani, Anna Citarella, Andrea Belisari, Guido Didoni, Lorenzo Giovanni Mantovani, Sabato Montella
Publikováno v:
Farmeconomia: Health Economics and Therapeutic Pathways, Vol 11, Iss 2, Pp 103-115 (2010)
In this study we compare the cost-effectiveness of saxagliptin (Onglyza®) in combination with metformin to that of either sulphonylurea (SU) plus metformin or a thiazolidinedione (TZD) plus metformin, in type 2 diabetes mellitus patients who are not
Externí odkaz:
https://doaj.org/article/4b6adee3807c4d0a84963db88fa7a94d
Publikováno v:
Farmeconomia: Health Economics and Therapeutic Pathways, Vol 10, Iss 2, Pp 93-97 (2009)
Introduction: metastatic renal cell carcinoma (mRCC) is highly resistant to chemotherapeutics, rendering limited antitumor effect. Temsirolimus, a specific inhibitor of the mammalian target of rapamycin kinase, may benefit patients with this disease.
Externí odkaz:
https://doaj.org/article/beb405d46ca841d4a3c84a345a344f89
Publikováno v:
Business Process Management Journal. 26:1-23
Purpose The purpose of this paper is to focus on the implementation of an ambidexterity strategy in a large Italian Company that works in the energy field. The aim of the study is to understand how contextual ambidexterity has been achieved during a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50bc1920ba9e1b98d10f3e518a6e2c9a
https://doi.org/10.1108/bpmj-06-2018-0158
https://doi.org/10.1108/bpmj-06-2018-0158